Kyle A Blum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3585152/publications.pdf

Version: 2024-02-01

687363 610901 24 671 13 24 h-index citations g-index papers 26 26 26 999 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies. Nature Immunology, 2022, 23, 904-915.	14.5	39
2	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2022, 12, 2308-2329.	9.4	7
3	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. European Urology Focus, 2021, 7, 381-389.	3.1	28
4	Single-cell sequencing links multiregional immune landscapes and tissue-resident TÂcells in ccRCC to tumor topology and therapy efficacy. Cancer Cell, 2021, 39, 662-677.e6.	16.8	179
5	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma – An exploratory analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 791.e17-791.e24.	1.6	3
6	The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. Urology, 2020, 136, 169-175.	1.0	9
7	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. European Urology Oncology, 2020, 3, 47-56.	5.4	20
8	Preoperative nomogram predicting 12-year probability of metastatic renal cancer – evaluation in a contemporary cohort. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 853.e1-853.e7.	1.6	6
9	Sarcomatoid renal cell carcinoma: biology, natural history and management. Nature Reviews Urology, 2020, 17, 659-678.	3.8	76
10	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nature Communications, 2020, 11, 4168.	12.8	46
11	An evaluation of the role of tumor load in cytoreductive nephrectomy. Canadian Urological Association Journal, 2020, 14, E625-E630.	0.6	1
12	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Scientific Reports, 2020, 10, 701.	3.3	21
13	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. Clinical Cancer Research, 2020, 26, 3629-3640.	7.0	30
14	Comparison of Cancer Specific Outcomes following Minimally Invasive and Open Surgical Resection of Early Stage Kidney Cancer from a National Cancer Registry. Journal of Urology, 2020, 203, 1094-1100.	0.4	9
15	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 916-923.	1.6	8
16	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 811.e9-811.e16.	1.6	6
17	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Modern Pathology, 2019, 32, 1344-1358.	5.5	49
18	Predicting the Impacted Ureteral Stone with Computed Tomography. Urology, 2019, 130, 43-47.	1.0	20

#	Article	IF	CITATION
19	Role of lymph node dissection in renal cell cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 187-192.	1.6	14
20	Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. Journal of Urology, 2018, 200, 275-282.	0.4	31
21	A contemporary lower pole approach for complete staghorn calculi: outcomes and efficacy. World Journal of Urology, 2018, 36, 1461-1467.	2.2	11
22	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. European Urology Focus, 2018, 4, 986-994.	3.1	29
23	Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma. European Urology Oncology, 2018, 1, 364-377.	5.4	21
24	The association of renal cell carcinoma with gastrointestinal stromal tumors. Journal of Surgical Oncology, 2018, 117, 1716-1720.	1.7	6